pharma · Hypertension
Innovent Biologics
Innovent Biologics (Suzhou) Co.
NovaPharmaNews editorial coverage mentioning Innovent Biologics — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- Suzhou, CN
- Founded
- 2011
- Employees
- 850
- Programs
- 2
- Drugs
- 3
- Patents
- 0
News & analysis
NovaPharmaNews articles mentioning Innovent Biologics — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning Innovent Biologics — regulatory, clinical, and market analysis.
Pharma bets on PD-1/VEGF bispecifics: Is lung cancer the wrong target?
While many drugmakers are focused on lung cancer for PD-1/VEGF bispecifics, emerging evidence shows the liver may offer higher value. This analysis covers the mechanism, key players, and strategic implications for pharma teams.
China: The Innovation Factor – Implications for Pharma BD and Investors
China has emerged as a global innovation powerhouse, now leading in 37 of 44 critical technologies. This article examines what this means for pharmaceutical deal-making, investment decisions, and competitive strategy for BD teams and executives.
Pfizer and Innovent's $10B Cancer Drug Deal: Key Insights
Pfizer and Innovent have entered a significant $10B deal focusing on cancer therapeutics. This article delves into the implications for the pharmaceutical landscape.